Arterys Cardio DL vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Arterys Cardio DL

by Arterys (now part of Tempus)

ElucidVivo A.3

by Elucid

AI Verdict

Tool A, Arterys Cardio DL, focuses on cardiac MRI analysis, providing automated ventricle segmentations and blood flow visualization to assess heart function. In contrast, Tool B, ElucidVivo A.3, specializes in quantitative analysis of arterial plaque composition from CT angiography to aid in atherosclerosis patient stratification. While both are AI-powered cardiovascular imaging tools, their distinct imaging modalities and specific clinical applications make them adjacent rather than direct competitors.

Choose Arterys Cardio DL if…

Choose Arterys Cardio DL if your primary need is to rapidly and accurately analyze cardiac MRI studies, focusing on automated ventricle segmentations, 4D flow dynamics, and quantitative delayed enhancement. This tool is ideal for improving efficiency and diagnostic precision in assessing myocardial function and viability, especially in high-volume cardiology and radiology practices.

View Arterys Cardio DL →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if your focus is on detailed, quantitative analysis of arterial plaque composition and stability from CT angiography. This tool is best suited for stratifying atherosclerosis patients and optimizing treatment decisions based on objective, histology-validated measurements of plaque characteristics like Lipid-Rich Necrotic Core (LRNC) and calcifications.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Arterys Cardio DL	ElucidVivo A.3
Deployment	Cloud-based (SaaS), integrates with existing PACS or EHR, web-based zero-footprint viewer (Mac, PC, tablet, phone). [4, 7, 9, 13, 27]	Cloud and on-premise secure deployment.
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Arterys Cardio DL

Arterys Cardio DL is a cloud-based solution designed for rapid analysis, reducing cardiac MRI interpretation time from minutes to seconds. Its editable automated contours further enhance user control and workflow efficiency, making it highly user-friendly.

Clinical Value

ElucidVivo A.3

ElucidVivo A.3 provides highly detailed, quantitative analysis of arterial plaque composition and stability from CT angiography, explicitly validated against ground-truth histology. This offers a deeper, more specific, and prognostically valuable insight into atherosclerosis, including the derivation of FFRct, which aids in patient stratification and treatment decisions.

Pricing & Value

Tie

Both Arterys Cardio DL and ElucidVivo A.3 require direct contact with the vendor for pricing information. Without transparent pricing, it is impossible to conduct a head-to-head comparison of their cost-effectiveness or overall value proposition.

Enterprise Readiness

Arterys Cardio DL

Arterys Cardio DL explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA). Its cloud-based deployment and vendor-agnostic compatibility further enhance its integration potential and readiness for enterprise-level healthcare IT infrastructures.

Innovation

Arterys Cardio DL

Arterys Cardio DL is recognized as the 'world's first internet platform for medical imaging' and the 'first technology to be cleared by the FDA that leverages cloud computing and deep learning in a clinical setting.' This represents a foundational innovation in the architectural approach and delivery model of AI in medical imaging.

Support & Docs

Tie

Both Arterys and Elucid Bioimaging indicate the availability of customer support and training on their respective websites. However, neither provides sufficient detailed information regarding the scope, channels, or depth of their support and documentation to clearly differentiate them.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Arterys Cardio DL	ElucidVivo A.3
Name	Arterys Cardio DL	ElucidVivo A.3
Company	ARTERYS	Elucid Bioimaging
Description	FDA-cleared, cloud-based AI software that provides automated, editable ventricle segmentations for cardiac MRI analysis, drastically reducing interpretation time and enhancing diagnostic accuracy.	FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography. It assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics validated against histology.
Key Functionality	Automated ventricle segmentations for cardiac MRI; 4D Flow post-processing; Quantitative Delayed Enhancement analysis	AI-powered quantitative analysis of arterial plaque from CT images; Visualizes lesion-level plaque composition; Derives fractional flow reserve (FFRct)
Primary Imaging Modality	Cardiac MRI	CT angiography

Videos

Demos, reviews, and walkthroughs featuring Arterys Cardio DL and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications of each AI tool?

Arterys Cardio DL focuses on automated, editable ventricle segmentations for cardiac MRI analysis, aiming to reduce interpretation time and enhance diagnostic accuracy for various cardiac conditions. ElucidVivo A.3 specializes in quantitative analysis of arterial plaque composition and stability from CT angiography to assist in atherosclerosis patient stratification and optimize treatment decisions.

Which imaging modalities are supported by each AI tool?

Arterys Cardio DL is specifically designed for the analysis of cardiac MRI images. In contrast, ElucidVivo A.3 is used for quantitative analysis of arterial plaque from CT angiography.

What specific quantitative insights do these tools provide to aid in diagnosis and treatment planning?

Arterys Cardio DL provides automated ventricle segmentations, 4D Flow post-processing for blood flow visualization and quantification, and quantitative Delayed Enhancement analysis. ElucidVivo A.3 offers quantitative analysis of arterial plaque components like Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications, and can derive fractional flow reserve (FFRct) based on vessel wall vasodilative capacity.

How do these tools contribute to patient management and decision-making?

Arterys Cardio DL enhances diagnostic accuracy and significantly reduces interpretation time for cardiac MRI, aiding in the assessment of cardiac function. ElucidVivo A.3 assists physicians in stratifying patients with atherosclerosis and optimizing treatment decisions by offering detailed visualization and measurement of plaque characteristics, which can help prevent adverse events like heart attack and stroke.

How has the analytical accuracy of each tool been validated?

Arterys Cardio DL is FDA-cleared and its deep learning algorithm was validated to produce results comparable to experienced clinical annotators, developed using data from several thousand cardiac cases. ElucidVivo A.3 is FDA-cleared and its quantitative analysis of arterial plaque composition and stability is explicitly validated against ground-truth histology.